NASDAQ:ALKSAlkermes Stock Price, Forecast & News

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALKS stock has increased by 15.0% and is now trading at $18.69.
View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Alkermes.

Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Alkermes.

Alkermes Plc (NASDAQ:ALKS) posted its earnings results on Wednesday, July, 29th. The company reported $0.06 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.19. The company had revenue of $247.53 million for the quarter, compared to analysts' expectations of $232.70 million. Alkermes had a positive return on equity of 4.47% and a negative net margin of 10.87%. Alkermes's quarterly revenue was down 11.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.09 earnings per share.
View Alkermes' earnings history.

Alkermes issued an update on its FY20 earnings guidance on Wednesday, July, 29th. The company provided EPS guidance of $0.00-0.19 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.11. The company issued revenue guidance of $965-1.005 billion, compared to the consensus revenue estimate of $983.05 million.

10 brokerages have issued twelve-month price targets for Alkermes' shares. Their forecasts range from $15.00 to $28.00. On average, they expect Alkermes' share price to reach $19.80 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for Alkermes.

News headlines about ALKS stock have been trending extremely negative this week, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alkermes earned a coverage optimism score of -4.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Alkermes.

Alkermes saw a decline in short interest in July. As of July 31st, there was short interest totaling 10,500,000 shares, a decline of 11.9% from the July 15th total of 11,920,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is currently 6.6 days. Approximately 6.7% of the company's stock are short sold.
View Alkermes' Short Interest.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Starbucks (SBUX), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Pfizer (PFE).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by many different retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (2.52%), UBS Group AG (1.24%), Russell Investments Group Ltd. (0.50%), Meditor Group Ltd (0.47%), Swiss National Bank (0.22%) and WINTON GROUP Ltd (0.22%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops.
View institutional ownership trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Rhenman & Partners Asset Management AB, Alps Advisors Inc., New York State Common Retirement Fund, and Arizona State Retirement System. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops.
View insider buying and selling activity for Alkermes.

ALKS stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, First Trust Advisors LP, MERIAN GLOBAL INVESTORS UK Ltd, WINTON GROUP Ltd, Russell Investments Group Ltd., Principal Financial Group Inc., Hardman Johnston Global Advisors LLC, and Platinum Investment Management Ltd..
View insider buying and selling activity for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $18.69.

Alkermes has a market capitalization of $2.97 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

The official website for Alkermes is www.alkermes.com.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]